Quantbot Technologies LP Buys Shares of 75,456 Organon & Co. $OGN

Key Points

• Quantbot Technologies LP acquired a new position in Organon & Co. by purchasing 75,456 shares, valued at approximately $1,124,000.
• Organon & Co. reported a quarterly EPS of $1.00, surpassing expectations of $0.94, with revenue of $1.59 billion for the quarter.
• The company declared a quarterly dividend of $0.02 per share, representing an annualized yield of 0.8% with a payout ratio of 2.97%.

Quantbot Technologies LP acquired a new stake in shares of Organon & Co. (NYSE:OGN - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 75,456 shares of the company's stock, valued at approximately $1,124,000.

Several other large investors have also bought and sold shares of OGN. Raymond James Financial Inc. bought a new position in Organon & Co. during the 4th quarter valued at $4,194,000. Canada Pension Plan Investment Board lifted its stake in Organon & Co. by 465.8% during the 4th quarter. Canada Pension Plan Investment Board now owns 21,500 shares of the company's stock valued at $321,000 after acquiring an additional 17,700 shares in the last quarter. GeoWealth Management LLC bought a new stake in shares of Organon & Co. during the 4th quarter worth $41,000. Dimensional Fund Advisors LP raised its stake in shares of Organon & Co. by 23.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,284,408 shares of the company's stock worth $48,999,000 after purchasing an additional 629,191 shares during the period. Finally, Stifel Financial Corp raised its stake in shares of Organon & Co. by 71.8% during the 4th quarter. Stifel Financial Corp now owns 405,528 shares of the company's stock worth $6,051,000 after purchasing an additional 169,447 shares during the period. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Stock Performance

Organon & Co. stock traded up $0.22 during midday trading on Friday, reaching $9.40. The stock had a trading volume of 4,579,414 shares, compared to its average volume of 4,767,843. Organon & Co. has a 12 month low of $8.01 and a 12 month high of $22.67. The firm's 50-day moving average price is $9.61 and its 200 day moving average price is $11.25. The firm has a market capitalization of $2.44 billion, a PE ratio of 3.49, a P/E/G ratio of 0.84 and a beta of 0.60. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 11.98.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $1.00 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.94 by $0.06. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.The business had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.55 billion. During the same period in the previous year, the business posted $1.12 EPS. The firm's quarterly revenue was down .8% compared to the same quarter last year. Organon & Co. has set its FY 2025 guidance at EPS. As a group, research analysts predict that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 11th. Investors of record on Friday, August 15th will be paid a $0.02 dividend. This represents a $0.08 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Friday, August 15th. Organon & Co.'s payout ratio is currently 2.97%.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Morgan Stanley lowered their target price on Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Evercore ISI cut Organon & Co. from an "outperform" rating to an "inline" rating in a research note on Friday, May 2nd. BNP Paribas upgraded Organon & Co. to a "strong-buy" rating in a research note on Thursday, May 22nd. Finally, Piper Sandler lowered their target price on Organon & Co. from $24.00 to $18.00 and set an "overweight" rating on the stock in a research note on Thursday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $18.00.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.